Our impact in 2017

How we are helping to create a world where no child dies of cancer

Children with Cancer UK
Keeping families together
A very warm thank you to every one of you for your kind support and for enabling us to invest our largest ever amount into paediatric and young person cancer research – your generous donations help to save the lives of children with cancer and keep families together.

This year, your funding has also allowed us to make our largest ever single grant. I’m pleased to say we have been able to invest £3.74M towards making Precision Medicine a reality for our young cancer patients.

Precision Medicine is a potentially ground-breaking method of treatment for children and young people with cancer, making the most of the latest genomic technologies to allow treatment to target the DNA of the tumour. This exciting new development means doctors can provide safer and kinder treatments for children and young people with cancer.

Supporting children with cancer so they can be with their families longer is another pillar of our work. We were pleased to be able to contribute to the development of two new patient family accommodation homes in 2017 – one in Bristol and the other in Southampton. We look forward to the doors opening, helping to keep families together throughout the long and difficult experience of cancer treatment.

2018 is a big year for us, as we celebrate 30 years of saving young lives. We look forward to continuing to fund even more vital specialist research that will take us closer to our vision of a world where no child dies from cancer.

I would like to extend my personal thanks to The Right Honourable the Earl Cadogan, who stepped down from his position as a Trustee in January this year. Lord Cadogan has been a trusted advisor, supporter and advocate of the charity for many years, bringing his invaluable experience to our Board of Trustees for over two decades. We wish him well in his retirement.

Thank you for all your support in 2017. With your continued help, I look forward to everything we can achieve as we continue to fight the injustice of cancer in children.

Eddie O’Gorman OBE
Founder and Chair of Trustees
2017 has been an exciting and challenging year for Children with Cancer UK, as we have geared up in preparation for a number of key transitions in 2018. Most important was the articulation of our long-term Vision and creating our 3-year Strategic Business Plan to drive growth, 2018 to 2020.

Having joined the organisation mid-way through 2017, fulfilling the roles of Chief Operating Officer and Chief Philanthropy Officer, I am delighted to have taken the helm as CEO from July 2018.

The recent launch of our new brand is the culmination of over 12 months’ work to develop our core value proposition and translate that in to our central brand identity. Our refreshed brand is truly embedded in the work of Children with Cancer UK and serves to amplify our purpose. The brand development followed from a Strategic Review that took place in 2017.

2017 has also seen Children with Cancer UK become a contender for the largest non-profit contributor to paediatric and young person cancer research in the UK. This is largely attributed to our commitment of £3.74M towards the Precision Medicine Initiative led by the Institute of Cancer Research. Precision Medicine is an innovative, emerging method of cancer treatment that enables targeted treatment of individual tumours in children. Early results of this research are very promising and indications are that this methodology can significantly advance the provision of safer and less-toxic treatments for young cancer patients, with excellent long-term quality of life outcomes.

With 2018 being Children with Cancer UK’s 30th anniversary, I am honoured to build on the incredible achievements to date; raising over £230M in support of childhood cancer is no easy feat and I sincerely applaud the dedication and drive of the O’Gorman family, the Trustees and the staff, over the past 30 years. I look forward to leading the charity on the next phase of its journey, to deliver even more exponential growth and impact. I hope we can continue to count on your commitment and support in helping us realise our vision of a world where no child dies of cancer. Thank you.
Today 12 families in the UK will be given the devastating news that their child has cancer.

With your support Children with Cancer UK continues to fund vital specialist research to help save the lives of children with cancer and keep their families together.
Our Vision

Our Vision is of a world where no child dies of cancer.

Our Mission is to improve survival rates and the quality of survival in young cancer patients and to find ways to prevent cancer in the future.

Our work has helped increase survival rates from 63.7% in 1990 to a predicted 84% in 2017*.

*Survival rates are based on 5 year survival. The 84% figure for 2017 is an estimated figure by the Office of National Statistics, exact figures will be known in 2023

Keeping families together

Bella's story

“Cancer is the scariest thing anyone could go through, especially when they are only two years of age. To hear that your baby has leukaemia, has got to be the hardest thing to hear.

Bella really struggled with chemotherapy and we spent month after month in the hospital. When one infection went, she seemed to catch another. At one point I thought that this nightmare would never end.

After 10 months of intensive chemotherapy which could be up to four doses of chemotherapy a day, Bella went on maintenance chemotherapy.

The difference in Bella is unbelievable. She is happy and has even started to eat again. Her eating is very limited but she is eating enough to say goodbye to the Nasogastric tube. We still have a long way to go and Bella will carry on receiving monthly chemotherapy through her port.

Bella is going from strength to strength and I am so proud of her. Bring on ringing that bell.

Her Mum, Lisa, tells their story.

Bella was diagnosed with acute lymphoblastic leukaemia in November 2016.
## Our year in numbers

### Research
- **£5.8M**
  - Our largest ever amount into vital specialist research
- **£3.74M**
  - on our Precision Medicine Initiative – our largest ever single grant
- **12**
  - new research projects
- **1**
  - International Science Conference

### Welfare
- **1,510**
  - exceptional grants to help families financially when they needed it the most
- **2 new**
  - patient and family accommodation houses
- **over 1,000**
  - children and young people with cancer in hospices around the UK

### Awareness
- **1**
  - Precision Medicine Initiative launch at the Houses of Parliament
- **456,856**
  - website sessions
- **630**
  - newspaper articles
- **14%**
  - increase in brand awareness survey
Investing in vital specialist research to save the lives of children with cancer

Zunairah’s story

“This was the day when our lives fell apart and our perfect world turned upside down.

Zuni’s treatment lasted over three years. Zunairah had a Nasogastric tube and a port on the left-hand side of her chest. This meant that Zuni was very fragile. The chemotherapy caused various dramatic changes in Zuni’s appearance. It started with Zuni gaining a large amount of weight, making her look tremendously chubby, even on her face. Zuni’s hair began to fall out due to the chemotherapy and soon she had no hair left. Following from this, she also ended up losing a large amount of weight. Our bubbly Zuni soon became moody. As a family we had to keep up with her anger issues and mood swings. Zuni even forgot how to walk. With the help of the nurses and doctors, as a family we worked together to get her walking."

Zunairah was diagnosed with acute lymphoblastic leukaemia on 20th January 2015 when she was only one. Zunairah’s Dad, Ayaze, tells their story.
How your donations helped children with cancer

We are pleased to report that our income for 2017 was £14.3M. We receive no government funding and rely exclusively on the generosity of our supporters.

For every £1 donated we spend 83p on fighting childhood cancer

50p  +  19p  +  14p  +  17p  =  £1
Research projects  Welfare projects  Raising awareness  Raising more money

For every £1 we spend on fundraising, we raise over £5 more

How we fundraised

Sports events  £4,410,962
Legacies  £1,259,919
Corporate and trust donations  £1,033,349
Scratch cards  £533,912
Appeals and associated donations  £3,717,331
Committed giving  £1,563,697
Community fundraising  £831,523
Helping more children with cancer ring the end of treatment bell

Caroline’s story

Chemotherapy and its appalling sickness floored Caroline, worsened by the morphine and anti-sickness steroids. Drugs upon drugs upon drugs caused a massive shock to her system. It was unbearable; heart breaking to witness her suffering and unspeakable to watch the chemotherapy ‘poison’ pumped into her.

Hair loss was a psychological trauma for Caroline. We cut a plait for her to keep and she stopped brushing her hair on learning it would fall out. She slowly came to terms with her baldness despite worries that the hair might re-grow a different colour.

When we were told that Caroline was in remission, the news was stunning; too much to take in. Caroline was withdrawn until we got home when she suddenly grabbed me for a rolling-around hug yelling “Yeah!!!!” repeatedly before going onto the trampoline and literally jumping for joy for about 10 minutes. There were many, many tears.

Cancer has left Caroline with various side effects which may increase over time including possible infertility and a paralysed vocal cord. Incredibly the remaining cord has compensated. It’s believed she has neurofibromatosis predisposing her to future lumps.

Caroline’s Mum, Lucy, tells their story

Caroline was diagnosed with parameningeal rhabdomyosarcoma (embryonal). She rang the end of treatment bell in August 2017.
We have invested £5.8M in vital specialist research to help more children ring the end of treatment bell

The high quality specialist research we fund is aimed at developing new treatments which are less toxic, and gentler on small bodies, giving survivors a better chance of a life free from health problems – and a cure for some of the hardest to treat cancers.

We are currently funding over 60 active research projects, worth over £20.5M, at centres of excellence around the UK. Our funding is helping to increase survival rates among children and young people moving us closer to our vision of a world where no child dies of cancer.

New research awards
In 2017, we made 12 new research project grants, totalling over £5.8M. All the research we fund is rigorously scrutinised by our Scientific Advisory Panel and reinforced by expert peer review. This ensures that we only support the highest quality research that will have the greatest impact in terms of patient care.

Precision Medicine: IMPACT
In 2017 we made our largest ever single grant, investing £3.74M towards making Precision Medicine a reality for young cancer patients. Unlike current methods, which make recommendations for treatment based on broad tumour categories, Precision Medicine uses detailed genetic analysis of individual tumours. This enables doctors to tailor cancer treatment to a particular child’s needs – taking into account their individual genetics and the changes in their tumour’s DNA.

This exciting new development means doctors can provide safer and kinder treatments for children and young people with cancer, giving more hope for survival with fewer side effects.

Lack of NHS funding has so far meant that the UK lagged behind the USA and Europe. Now, through the project known as IMPACT (Individualising Management of Paediatric Cancer Treatment), Professor Louis Chesler and his team at the Institute of Cancer Research, London, are exploring this potentially game-changing approach to treating children’s cancers.

The aim is for all young cancer patients in the UK to have Precision Medicine as a key part of their treatment options through the NHS.
Application of modern technologies to treatment is very important because it maximises the chance that this new generation of ‘targeted’ cancer drugs can be most effective, by matching patients to the best drug using the most precise genetic information about their tumour. A more comprehensive and structured approach to genetic testing to match children with cancer to specific targeted treatments could be an incredibly important step towards increasing survival.

Professor Louis Chesler  
Institute of Cancer Research

The need for finding kinder, more effective treatments

Dylan’s story

“’The day of the surgery was long and difficult for all of us. Taking Dylan to theatre knowing that it may be the last time I saw, kissed or held him was torture. I lost count of how many times I wanted to just turn and run with him in my arms, and keep on running until this nightmare was over.

Unfortunately the nightmare has continued and Dylan’s cancer has regrown and spread at an alarming rate. Dylan needs further, more aggressive, more dangerous, more risky, more damaging treatment.

But above all, Dylan, and all the other children with cancer, need kinder, less damaging and less toxic treatment protocols. These children need the chance to be able to beat cancer and still lead long, happy and healthy lives.

Dylan’s Mum, Jessica, shares their story

Dylan was diagnosed with medulloblastoma in 2014
We have invested £5.8M in specialist research to help survivors live a better life

 Sadly, for some children, ringing their end of treatment bell doesn’t mean a return to normal life. Survivors of childhood cancer aren’t likely to live as long as the rest of the population, and some live with severe side effects from their illness and the toxic treatments currently needed to treat it. As well as funding research into new, gentler treatments, we’ve funded a project to help doctors understand which children and young people are at greatest risk of future side effects.

Blame diagnosed with medulloblastoma when he was three years old

Sharing learning for the greater good of all

With support from Children with Cancer UK, Professor Hawkins and his team at the University of Birmingham are studying the national population of survivors of childhood, teenage and young adult cancer, to identify those with the most side effects from their treatment. The team have data on all 35,000 survivors of childhood cancer diagnosed between 1940 and 2006 in Britain, together with data on all 200,000 survivors of teenage and young adult cancer diagnosed between 1971 and 2006 in England and Wales.

They will work out those who have since passed away, those who developed further cancers, and those who were hospitalised. The data will enable them to estimate the total risk of side effects, and then to see whether this risk varies by type of cancer diagnosed, types of cancer treatment received and other factors.

Helping doctors and nurses understand who is at low, medium and high risk of side effects will enable them to plan future treatments for children with cancer with a view to giving future survivors a better life.

Funding causes

Children with Cancer UK has agreed to continue funding a database for the World Health Organisation’s International Agency for Research on Cancer that we helped to establish in 2013. This is collecting research results on environmental and other causes of childhood cancer, from studies around the world. It is really starting to make progress into finding some causes of childhood cancer (not just leukaemia) so that we can start to do something to reduce the number of children who develop cancer.

Science Conference

In 2017 we held our first scientific and medical conference outside of London. The venue was near a centre of medical research excellence at Newcastle upon Tyne, which Children with Cancer UK played a significant part in funding.

130 people registered for the conference, including the highest number of young researchers that have ever attended one of our meetings.
We funded innovative welfare projects

Helping to support children with cancer and their families

When a family gets the worst news, that a child has cancer, it’s devastating and everything changes. Normal life gets put on hold whilst the family focuses on their child’s treatment.

In 2017 Children with Cancer UK awarded £1.4M to help make life more bearable for young cancer patients and their families through our welfare projects.

Patient and Family Accommodation
Through partnerships with CLIC Sargent and Bristol Royal Hospital for Children we have helped to fund more patient family accommodation homes serving hospitals in Bristol and Southampton. The warm, friendly accommodation gives families somewhere to stay together, close to where their child is being treated, but away from the hospital ward, providing a sanctuary where families can spend precious time together.

Financial support for families
In 2017, helped by our funding, 1,510 families were able to receive financial assistance through the CLIC Sargent grants programme.

Families with a child with cancer will spend on average £600 a month on additional expenses during treatment. So these grants provide families with vital financial support, giving them one less thing to worry about.

Assistive technology for patients when they need it the most
Through our grant to Lifelites, in 2017 we helped to support 1,000 young cancer patients with free assistive technology in hospices around the UK. This extraordinary technology helps children to communicate, express their feelings, and experience the delights of creating music, playing games with their families and sharing precious memories together.

Zippos Circus
In September we welcomed nearly 50 families as VIP guests at a very special performance of Zippos Circus, featuring high-energy acts from across the world. After the show, the children and their families enjoyed meeting some of the wonderful performers, helping to create unforgettable memories.
Caoilfhionn was diagnosed with a neuroblastoma when she was one year old

Keeping families together during treatment

Caoilfhionn’s story

During the first weeks of Caoilfhionn’s treatment we basically lived in the hospital, which was 75 miles from our home. We hadn’t thought about the financial impact, but we certainly noticed it when it hit us. Every journey was costing us about £20 and that is before you’re worrying about feeding yourself.

Following surgery it was then a horrible wait for the tumour report to come back. We ended up finding out a couple of days before Christmas that she would not need chemotherapy and that the tumour had stayed in one piece. It was just a case of follow-up treatment, but no more major treatment. It was a great Christmas present.

When we were offered accommodation in the Home, the difference it made to us was just unbelievable. Suddenly you can take a moment to rest. The exhaustion can be overwhelming and this helped so much.

Caoilfhionn’s Mum, Karen, tells their story
We raised awareness of cancer in children and young people

We receive no government funding for our work, despite the desperate need for research into new treatments for childhood cancers. Raising awareness is a vital part of our work.

Precision Medicine launch at Parliament
In March, we were very proud to launch our Precision Medicine Initiative at the House of Commons. We were delighted with the number of MPs, scientists, celebrities and families affected by childhood cancer who joined us to celebrate. We were also thrilled to receive national media coverage from Sky News and The Sunday Telegraph, highlighting the potential difference Precision Medicine could make to young cancer patients.

Our brand new website
In May 2017 we launched our new website. It’s not only easier to navigate and use, but is also fully mobile responsive and will be easier to expand in the future. The new site allows us to gain greater insights into how people are interacting with us, which will guide future improvements and developments.

Central to the new website has been the need to make it easier for supporters to get involved with Children with Cancer UK, so we are delighted that traffic and donations from the new site have increased since it went live.

Childhood Cancer Awareness Month:
Golden Moments Campaign
During September 2017 we once again took part in Childhood Cancer Awareness Month, when the world unites to raise awareness of cancer in children and young people. To mark it, we launched our Golden Moments campaign. It focussed on the positive experiences families can have during their childhood cancer journey, and sought to give hope to families currently undergoing treatment.

Dozens of families sent in their own ‘Golden Moments’ from their child’s cancer journey and we created a special wall on our website for them.

We created a special Childhood Cancer Awareness Month social media frame for supporters to use, which was downloaded by 4,000 people. One of our supporters also shared a very moving visual podcast detailing her daughter’s battle with cancer.
Thought I would send you one of our golden moments so far and there have been quite a few but this really is special, it’s hard as at times throughout this horrible process, you see your child all weak, being sick and telling you they want it to stop and to go away and then you see your child 8 months down the road with a huge grin on her face starting her life in primary school on her first day with her gorgeous sister!!! Daisy is such an inspiration and we love her strength and determination.

Darren, Daisy’s Dad

This is my beautiful daughter Ruby holding her little sister Willow for the first time.

Lisa, Ruby’s Mum

Our Golden Moment was ringing the end of treatment bell on the ward at the Queen’s Medical Centre in Nottingham. This was the day Alice who is 7 had her port removed after fighting cancer a second time – relapsed Wilms. The bell wasn’t there when we finished treatment the first time so it was a really special moment to ring it loud and clear when we reached the end of a very difficult 3 year journey, surrounded by family, nurses and patients we had got to know. Alice is now over one year in remission and just started junior school.

Darren, Alice’s Dad
Our fundraising highlights

How you showed your support and helped to raise £14.3M in 2017

We are extremely thankful to all our supporters and fundraisers, who have made our work in 2017 possible. Your energy, enthusiasm and positivity have made a huge difference and together we can achieve our vision of a world where no child dies of cancer.

Virgin Money London Marathon
£2.9M

Fire and Ice Ball
£40,000

Opera at Syon
£135,000

The Children with Cancer UK Ball
£610,000

Spring into Summer Party
£49,000

Prudential RideLondon
£320,000

Great North Run
£120,000

Rat Race
£400,000

The White Collar Boxing Company
£28,000

Linda’s Lottery
£500,000

Team Will LXX
£58,000
2017 was the year Benji finished treatment!

Benji had his last intravenous chemotherapy and steroids in October 2017 and his last oral chemotherapy on 20th November 2017, which marked the end of his treatment! Obviously we were very excited about this but somewhat nervous. As much as we were ready for treatment to finish, it feels like we have lost our safety net, but we are confident that Benji will continue to live a happy and healthy life. Benji is very excited to have his last Chemo and is looking forward to having lots of overdue adventures in 2018 when he hopes he will be able to go on a plane to Lapland and a summer holiday with all his family to Italy.

Benji was diagnosed with acute lymphoblastic leukaemia in September 2014. His Mum, Louise, told their story
Thank you

We are immensely grateful to all our amazing supporters and fundraisers, who helped us to raise the huge total of £14.3M in 2017.

Corporate Partners:
- Coral
- Mr. Men Little Miss
- RS Components

All those who played a part in our our successful fundraising events:
- Caroline Randerson
- Lady Julia Craig Harvey and Mrs Peter Hargreaves-Allen, Chairs of the Opera at Syon Committee, and the Committee Members
- Stephen Haines, Chair of The Children with Cancer UK Ball Committee, and Committee Members
- Richard Harley, Chair of the Quiz Party Committee, and Committee Members

Everyone who has helped us fundraise through sporting and community events:
- London Marathon Events
- Rat Race Events
- White Collar Boxing Company
- Top Model
- Team Will LXX

Our dedicated and generous Trustees:
- Eddie O’Gorman OBE, Founder and Chair of Trustees
- Sandra Mileham
- Linda Robson
- Alasdair Maclean Philips BSc, DAgE, MIAgE, MIEEE
- The Rt Hon the Earl Cadogan KBE DL (stepped down 12th January 2018)
- Russell Smith (Appointed 12th January 2018)

We offer huge gratitude to all our supporters and volunteers for their help in keeping families together in 2017.

A very special and deep thank you goes to all the extraordinary families who have shared their experiences in 2017. Your involvement is central to our work, and your help in raising awareness and vital funds to help young cancer patients is invaluable.
### Accounts

**Report by the Trustees on the Summarised Financial Statements**

The Summarised Financial Statements are extracted from the full statutory Trustees Annual Report and Financial Statements as approved by the Trustees. The Trustees Annual Report and Financial Statements and Auditor’s Report may be obtained from Children with Cancer UK, 51 Great Ormond Street, London WC1N 3JQ or childrenwithcancer.org.uk.

**Consolidated statement of financial activities for the year ended 31 December 2017**

(Incorporating an income and expenditure account)

<table>
<thead>
<tr>
<th></th>
<th>Restricted funds (£)</th>
<th>Unrestricted funds (£)</th>
<th>2017 (£)</th>
<th>2016 (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Income from</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donations and legacies</td>
<td>413,750</td>
<td>12,936,943</td>
<td>13,350,693</td>
<td>15,582,421</td>
</tr>
<tr>
<td>Other trading activities</td>
<td>–</td>
<td>867,174</td>
<td>867,174</td>
<td>750,973</td>
</tr>
<tr>
<td>Income from investments</td>
<td>–</td>
<td>106,057</td>
<td>106,057</td>
<td>142,735</td>
</tr>
<tr>
<td>Other income</td>
<td>–</td>
<td>8,423</td>
<td>8,423</td>
<td>48,287</td>
</tr>
<tr>
<td><strong>Total income</strong></td>
<td>413,750</td>
<td>13,918,597</td>
<td>14,332,347</td>
<td>16,524,416</td>
</tr>
<tr>
<td><strong>Expenditure on</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raising funds</td>
<td>–</td>
<td>2,606,851</td>
<td>2,606,851</td>
<td>2,520,561</td>
</tr>
<tr>
<td>Charitable activities</td>
<td>203,546</td>
<td>12,908,999</td>
<td>13,112,545</td>
<td>11,791,787</td>
</tr>
<tr>
<td><strong>Total expenditure</strong></td>
<td>203,546</td>
<td>15,515,850</td>
<td>15,719,396</td>
<td>14,312,348</td>
</tr>
<tr>
<td>Net change in investments</td>
<td>–</td>
<td>101,977</td>
<td>101,977</td>
<td>186,499</td>
</tr>
<tr>
<td><strong>Net income (expenditure)</strong></td>
<td>210,204</td>
<td>(1,495,276)</td>
<td>(1,285,072)</td>
<td>2,398,567</td>
</tr>
<tr>
<td>Transfers between funds</td>
<td>(210,204)</td>
<td>210,204</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Net movement in funds</strong></td>
<td>–</td>
<td>(1,285,072)</td>
<td>(1,285,072)</td>
<td>2,398,567</td>
</tr>
<tr>
<td>Reconciliation of funds</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total funds brought forward</td>
<td>–</td>
<td>10,829,380</td>
<td>10,829,380</td>
<td>8,430,813</td>
</tr>
<tr>
<td>Total funds carried forward</td>
<td>–</td>
<td>9,544,308</td>
<td>9,544,308</td>
<td>10,829,380</td>
</tr>
</tbody>
</table>
## Balance Sheet as at 31 December 2017

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group (£)</td>
<td>Charity (£)</td>
<td>Group (£)</td>
<td>Charity (£)</td>
</tr>
<tr>
<td><strong>Fixed assets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investments</td>
<td>14,581,097</td>
<td>14,581,197</td>
<td>10,417,452</td>
<td>10,417,552</td>
</tr>
<tr>
<td><strong>Current assets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Debtors and prepayments</td>
<td>3,014,771</td>
<td>3,114,043</td>
<td>2,351,499</td>
<td>2,387,565</td>
</tr>
<tr>
<td>Cash deposits</td>
<td>4,338,183</td>
<td>4,338,183</td>
<td>10,272,332</td>
<td>10,272,332</td>
</tr>
<tr>
<td>Cash at bank and in hand</td>
<td>1,136,997</td>
<td>1,002,302</td>
<td>402,077</td>
<td>366,152</td>
</tr>
<tr>
<td><strong>Total assets less</strong></td>
<td><strong>8,489,951</strong></td>
<td><strong>8,454,528</strong></td>
<td><strong>13,025,908</strong></td>
<td><strong>13,026,049</strong></td>
</tr>
<tr>
<td><strong>Creditors:</strong> Amounts</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>falling due within one</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>year</td>
<td>(6,869,160)</td>
<td>(6,869,160)</td>
<td>(6,303,885)</td>
<td>(6,303,885)</td>
</tr>
<tr>
<td>Other</td>
<td>(715,508)</td>
<td>(725,717)</td>
<td>(678,968)</td>
<td>(679,209)</td>
</tr>
<tr>
<td><strong>Net current assets</strong></td>
<td><strong>905,283</strong></td>
<td><strong>859,651</strong></td>
<td><strong>6,043,055</strong></td>
<td><strong>6,042,955</strong></td>
</tr>
<tr>
<td><strong>Total assets less</strong></td>
<td><strong>15,486,360</strong></td>
<td><strong>15,440,848</strong></td>
<td><strong>16,460,507</strong></td>
<td><strong>16,460,507</strong></td>
</tr>
<tr>
<td><strong>Creditors:</strong> Amounts</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>falling due after more</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>than one year</td>
<td>(5,942,072)</td>
<td>(5,942,072)</td>
<td>(5,631,127)</td>
<td>(5,631,127)</td>
</tr>
<tr>
<td><strong>Net assets</strong></td>
<td><strong>9,544,308</strong></td>
<td><strong>9,498,776</strong></td>
<td><strong>10,829,380</strong></td>
<td><strong>10,829,380</strong></td>
</tr>
<tr>
<td>Represented by</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted funds</td>
<td>9,544,308</td>
<td>9,498,776</td>
<td>10,829,380</td>
<td>10,829,380</td>
</tr>
<tr>
<td>Restricted funds</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>9,544,308</strong></td>
<td><strong>9,498,776</strong></td>
<td><strong>10,829,380</strong></td>
<td><strong>10,829,380</strong></td>
</tr>
</tbody>
</table>
## Accounts

### Grants to third parties

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Project Description</th>
<th>Cost (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Research UK</td>
<td>Individualising Management of Paediatric Cancer Treatment – IMPACT</td>
<td>2,240,000</td>
</tr>
<tr>
<td>Professor Louis Chesler, Institute for Cancer Research</td>
<td>Individualising Management of Paediatric Cancer Treatment – IMPACT</td>
<td>–</td>
</tr>
<tr>
<td>CLIC Sargent</td>
<td>Home from Home in Southampton, providing patient and family accommodation close to Southampton General Hospital</td>
<td>–</td>
</tr>
<tr>
<td>CLIC Sargent</td>
<td>to their Grants Fund, which provides financial assistance to the families of children being treated for cancer</td>
<td>–</td>
</tr>
<tr>
<td>Bristol Children’s Hospital</td>
<td>– Providing Family Accommodation at Bristol Children’s Hospital</td>
<td>–</td>
</tr>
<tr>
<td>Professor Michael Hawkins, University of Birmingham</td>
<td>Risk stratification of the national population of survivors of childhood, teenage and young adult cancer for evidence-based clinical follow-up</td>
<td>–</td>
</tr>
<tr>
<td>Dr Audrey Bonaventure, London School of Hygiene and Tropical Medicine</td>
<td>Global surveillance of survival from haematological malignancies in children, teenagers and young adults</td>
<td>–</td>
</tr>
<tr>
<td>Dr John Moppett, Bristol Royal Hospital for Children</td>
<td>A pilot study to test the feasibility of delivering an integrated risk stratification algorithm for multi-centre trials in childhood Leukaemia</td>
<td>–</td>
</tr>
<tr>
<td>Dr Owen Williams, UCL Great Ormond Street Institute for Child Health</td>
<td>Harnessing SMAD7 induced transcriptional pathways for novel anti-Leukaemia therapies</td>
<td>–</td>
</tr>
<tr>
<td>Dr Oleg Gerasimenko, Cardiff University</td>
<td>Modification of the Asparaginase-based drugs for ALL</td>
<td>–</td>
</tr>
<tr>
<td>Professor Sibylle Mittnacht, UCL Cancer Institute</td>
<td>Exploring retinoblastoma protein loss as an actionable target in paediatric bone and soft tissue sarcoma</td>
<td>–</td>
</tr>
<tr>
<td>Dr Rachael Nimmo, UCL Cancer Institute</td>
<td>Targeting RUNX/Core Binding Factor-dependency in relapsed and poor prognosis acute lymphoblastic leukaemia</td>
<td>–</td>
</tr>
<tr>
<td>Professor Olaf Heidenreich, Newcastle University</td>
<td>Non-genotoxic combination treatments for paediatric Acute Leukaemias</td>
<td>–</td>
</tr>
<tr>
<td>Dr Christina Halsey (Extension of existing grant), University of Glasgow</td>
<td>Biomarkers and discovery of new therapeutic targets for chemotherapy associated neurotoxicity</td>
<td>–</td>
</tr>
<tr>
<td>Claire Hislop</td>
<td>Neuroblastoma Parent Education Conference (2017)</td>
<td>–</td>
</tr>
<tr>
<td>Suzanne Turner</td>
<td>8th Annual Meeting of the European Research Initiative for ALK-Related Malignancies (ERIA)</td>
<td>–</td>
</tr>
</tbody>
</table>

**Total grants to third parties**

268,340 5,553,033 1,392,000 10,000 7,223,373
<table>
<thead>
<tr>
<th>Research into prevention and causes 2017 (£)</th>
<th>Research into treatment 2017 (£)</th>
<th>Welfare 2017 (£)</th>
<th>Education 2017 (£)</th>
<th>Total 2017 (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>–</td>
<td>2,240,000</td>
<td>–</td>
<td>–</td>
<td>2,240,000</td>
</tr>
<tr>
<td>–</td>
<td>1,500,000</td>
<td>–</td>
<td>–</td>
<td>1,500,000</td>
</tr>
<tr>
<td>–</td>
<td></td>
<td>690,000</td>
<td>–</td>
<td>690,000</td>
</tr>
<tr>
<td>–</td>
<td></td>
<td>332,000</td>
<td>–</td>
<td>332,000</td>
</tr>
<tr>
<td>–</td>
<td></td>
<td>250,000</td>
<td>–</td>
<td>250,000</td>
</tr>
<tr>
<td>–</td>
<td>249,842</td>
<td>–</td>
<td>–</td>
<td>249,842</td>
</tr>
<tr>
<td>–</td>
<td>249,178</td>
<td>–</td>
<td>–</td>
<td>249,178</td>
</tr>
<tr>
<td>248,400</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>248,400</td>
</tr>
<tr>
<td>–</td>
<td>245,852</td>
<td>–</td>
<td>–</td>
<td>245,852</td>
</tr>
<tr>
<td>–</td>
<td>239,242</td>
<td>–</td>
<td>–</td>
<td>239,242</td>
</tr>
<tr>
<td>–</td>
<td>237,514</td>
<td>–</td>
<td>–</td>
<td>237,514</td>
</tr>
<tr>
<td>–</td>
<td>182,907</td>
<td>–</td>
<td>–</td>
<td>182,907</td>
</tr>
<tr>
<td>19,940</td>
<td>–</td>
<td>120,000</td>
<td>–</td>
<td>19,940</td>
</tr>
<tr>
<td>–</td>
<td>11,478</td>
<td>–</td>
<td>–</td>
<td>11,478</td>
</tr>
<tr>
<td>–</td>
<td>6,000</td>
<td>–</td>
<td>–</td>
<td>6,000</td>
</tr>
<tr>
<td><strong>268,340</strong></td>
<td><strong>5,553,033</strong></td>
<td><strong>1,392,000</strong></td>
<td><strong>10,000</strong></td>
<td><strong>7,223,373</strong></td>
</tr>
</tbody>
</table>
Setting our Strategy for the future

2018-2020

In 2017 we undertook a Strategic Review to set our direction until 2020.

Tragically cancer still causes the most deaths for children aged 0-14 years old and there are now 35,000 cancer survivors who may have long-term health problems associated with their treatment.

There is still so much more that can be done to help us achieve our Vision. As we look to the future, we will be funding even more ground-breaking research, innovative welfare projects to support families, and raise awareness of childhood cancers.

**Our Strategic Goals**

- To become, and continue to hold position, as the UK’s largest not-for-profit financial contributor to paediatric and young person cancer research
- To grow net income available for investment in Charitable Activities to £15M per annum by 2020

**Our Vision**

Our Vision is a world where no child dies of cancer

**Our Mission**

To improve survival rates and the quality of survival in young cancer patients and to find ways to prevent cancer in the future

**Our Brand Promise**

We actively raise and invest money for vital specialist research to help save the life of every child and young person with cancer and keep their family together
How we are going to achieve our Strategy

From our new Strategy we have identified aims and measures to demonstrate what we strive to achieve by 2020:

- We will aim to be the biggest not-for-profit annual financial contributor to research into cancer in children and young people in the UK
- We will maintain a place in the top 100 UK charities, based on fundraising activity
- We will continue to support respite homes and associated financial support for children and families affected by childhood cancer
- We will fund high quality research aimed at developing treatments which are not only more effective but less debilitating and disruptive to young lives
- We will contribute to peer reviewed research into the discovery and reduction of causes of cancer, including directly supporting the work of the International Agency for Research in Cancer (IARC, part of WHO)
- We will provide capital funding to encourage the development of centres of excellence in childhood cancer research
- We will raise public awareness about our activities and the results of relevant research
- We will seek to influence the development of policy to promote the best interests of children with or at risk of cancer
- We will continue to be a highly engaged and effective organisation that recognises and rewards the right behaviours, innovation and outcomes for the organisation and for those we help
Helping to save the lives of children with cancer and keep their families together

Children with Cancer UK is the leading national children's charity dedicated to fighting the injustice of cancer in children.

Download our complete Annual Report and Accounts 2017 and full list of our Grant Awards at childrenwithcancer.org.uk.

Registered Charity Number: 298405.
Inaugurated by Diana, Princess of Wales
A company limited by guarantee. Registered in England Number: 4960054.
51 Great Ormond Street, London WC1N 3JQ. 020 7404 0808 info@childrenwithcancer.org.uk